JP2016504389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504389A5 JP2016504389A5 JP2015551862A JP2015551862A JP2016504389A5 JP 2016504389 A5 JP2016504389 A5 JP 2016504389A5 JP 2015551862 A JP2015551862 A JP 2015551862A JP 2015551862 A JP2015551862 A JP 2015551862A JP 2016504389 A5 JP2016504389 A5 JP 2016504389A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- mgbg
- fingolimod
- disease
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 11
- 229960000556 fingolimod Drugs 0.000 claims 11
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 11
- 208000016192 Demyelinating disease Diseases 0.000 claims 9
- 238000004519 manufacturing process Methods 0.000 claims 6
- 229960003539 mitoguazone Drugs 0.000 claims 6
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 4
- 108010005716 Interferon beta-1a Proteins 0.000 claims 4
- 108010005714 Interferon beta-1b Proteins 0.000 claims 4
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 4
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims 4
- 229960004419 dimethyl fumarate Drugs 0.000 claims 4
- 229960003776 glatiramer acetate Drugs 0.000 claims 4
- 229960004461 interferon beta-1a Drugs 0.000 claims 4
- 229960003161 interferon beta-1b Drugs 0.000 claims 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 4
- 229960001156 mitoxantrone Drugs 0.000 claims 4
- 229960005027 natalizumab Drugs 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims 4
- 229960000331 teriflunomide Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 3
- 229960004577 laquinimod Drugs 0.000 claims 3
- 230000006472 autoimmune response Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000036546 leukodystrophy Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000008795 neuromyelitis optica Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 1
- 208000011403 Alexander disease Diseases 0.000 claims 1
- 208000022526 Canavan disease Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 206010010252 Concentric sclerosis Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000028226 Krabbe disease Diseases 0.000 claims 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 102000006386 Myelin Proteins Human genes 0.000 claims 1
- 108010083674 Myelin Proteins Proteins 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000030597 adult Refsum disease Diseases 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000005012 myelin Anatomy 0.000 claims 1
- 230000023105 myelination Effects 0.000 claims 1
- -1 natalizumab Chemical compound 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750336P | 2013-01-08 | 2013-01-08 | |
| US61/750,336 | 2013-01-08 | ||
| US201361823276P | 2013-05-14 | 2013-05-14 | |
| US61/823,276 | 2013-05-14 | ||
| PCT/US2014/010714 WO2014110154A1 (en) | 2013-01-08 | 2014-01-08 | Methods and comp0stions for treatment of demyelinating diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018130715A Division JP2018172427A (ja) | 2013-01-08 | 2018-07-10 | 脱髄疾患の治療のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504389A JP2016504389A (ja) | 2016-02-12 |
| JP2016504389A5 true JP2016504389A5 (enExample) | 2017-02-16 |
| JP6370804B2 JP6370804B2 (ja) | 2018-08-08 |
Family
ID=51167347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551862A Expired - Fee Related JP6370804B2 (ja) | 2013-01-08 | 2014-01-08 | 脱髄疾患の治療のための方法および組成物 |
| JP2018130715A Pending JP2018172427A (ja) | 2013-01-08 | 2018-07-10 | 脱髄疾患の治療のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018130715A Pending JP2018172427A (ja) | 2013-01-08 | 2018-07-10 | 脱髄疾患の治療のための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10085955B2 (enExample) |
| EP (2) | EP3831372A1 (enExample) |
| JP (2) | JP6370804B2 (enExample) |
| CN (2) | CN105163730B (enExample) |
| AU (2) | AU2014205529B2 (enExample) |
| BR (1) | BR112015016189A8 (enExample) |
| CA (1) | CA2896977C (enExample) |
| DK (1) | DK2943189T3 (enExample) |
| ES (1) | ES2859553T3 (enExample) |
| IL (1) | IL239851B (enExample) |
| WO (1) | WO2014110154A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033487T2 (en) | 2007-03-09 | 2017-12-28 | Pathologica Llc | MGBG for osteopontin control and multiple sclerosis treatment |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| DK2453886T3 (en) | 2009-07-16 | 2019-03-25 | Pathologica Llc | ORGANIC ADMINISTRATION COMPREHENSIVE MGBG AND DISEASE METHODS |
| US8858991B2 (en) | 2011-01-19 | 2014-10-14 | Pathologica Llc | Delayed release oral pharmaceutical dosage forms comprising MGBG |
| AU2014205529B2 (en) | 2013-01-08 | 2018-08-09 | Pathologica Llc | Methods and compositions for treatment of demyelinating diseases |
| US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
| MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| EP3118621A1 (en) * | 2015-07-14 | 2017-01-18 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy |
| US20180250284A1 (en) * | 2015-09-08 | 2018-09-06 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Quinoline derivatives for use in treating leukodystrophy and treatment method |
| SG11201806797UA (en) * | 2016-03-07 | 2018-09-27 | Univ Osaka | Sustained drug release sheet for treating nerve injury |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| MX2019010174A (es) | 2017-03-26 | 2019-10-15 | Mapi Pharma Ltd | Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple. |
| SG11202010087UA (en) * | 2018-04-13 | 2020-11-27 | Mordechai Chevion | Compositions and methods for treatment of demyelination |
| JP7730816B2 (ja) * | 2019-12-19 | 2025-08-28 | アクティブ バイオテック エービー | 過剰血管新生に関連する眼疾患を治療する化合物 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4201788A (en) | 1976-10-20 | 1980-05-06 | University Patents, Inc. | Process for alleviating proliferative skin diseases |
| US5614557A (en) | 1977-07-11 | 1997-03-25 | Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. | Method of controlling tumor growth rate |
| US4520031A (en) | 1981-06-01 | 1985-05-28 | The United States Of America As Represented By The Secretary Of Department Of Health And Human Services | Method for reducing toxic effects of methyl-glyoxal bis-guanylhydrazone |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| US5580715A (en) | 1994-08-05 | 1996-12-03 | The Regents Of The University Of California | Diagnosis of cancer having clonal macrophage involvement |
| US5698563A (en) | 1995-01-13 | 1997-12-16 | Alteon Inc. | Bis- hydrazones! |
| EP1459745A3 (en) | 1996-09-13 | 2004-12-15 | University Of Florida Research Foundation, Inc. | Method of inhibiting biosynthesis of elf5a |
| AR009380A1 (es) | 1996-10-21 | 2000-04-12 | Sumitomo Chemical Co | Proceso de preparacion de un derivado de piridazin-3-ona, util como herbicida, acido carboxilico de utilizacion en el mismo, sal de este ultimo y proceso para preparar dicho acido carboxilico |
| US6083496A (en) | 1996-10-22 | 2000-07-04 | Universite Laval | Polyamine transport inhibitors |
| CA2297413A1 (en) | 1997-07-15 | 1999-01-28 | Oridigm Corporation | Novel polyamine analogues as therapeutic and diagnostic agents |
| US5889061A (en) | 1997-10-15 | 1999-03-30 | Wisconsin Alumni Research Foundation | Conformationally restricted polyamines |
| US8198334B2 (en) | 1997-10-27 | 2012-06-12 | Pathologica Llc | Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| US6169115B1 (en) | 1998-05-22 | 2001-01-02 | Rima Kaddurah-Daouk | Use of aminoguanidine analogs for the treatment of diseases of the nervous system |
| HK1040993B (en) | 1999-04-30 | 2006-11-10 | Cellgate, Inc. | Polyamines and their use in therapy |
| US6544541B1 (en) | 1999-06-02 | 2003-04-08 | Cardiovascular Solutions, Inc. | Devices and compounds for treating arterial restenosis |
| EP1261361B1 (en) * | 2000-02-18 | 2006-06-14 | Yeda Research And Development Company, Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 (glatiramer acetate) |
| AU2002235126A1 (en) | 2000-11-08 | 2002-05-21 | Slil Biomedical Corporation | Novel polyamine analog-amino acid conjugates useful as anticancer agents |
| US7754765B2 (en) | 2000-12-01 | 2010-07-13 | Radical Vision Therapeutics Inc | Copper chelators for treating ocular inflammation |
| CN100582084C (zh) | 2001-01-08 | 2010-01-20 | 麦迪凯斯特治疗学股份有限公司 | 疏水性多胺类似物及其使用方法 |
| CA2456034A1 (en) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
| US7045550B2 (en) | 2001-08-07 | 2006-05-16 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
| US6924095B2 (en) | 2001-08-15 | 2005-08-02 | The Regents Of The University Of California | Retrovirus isolated from mantle histiocytes in mantle cell lymphoma |
| US7273888B2 (en) | 2001-11-16 | 2007-09-25 | Als Therapy Development Foundation, Inc. | Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis |
| AU2002357748A1 (en) * | 2001-11-21 | 2003-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Osteopontin-related compositions and methods |
| US7622117B2 (en) | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
| EP1389480A1 (en) * | 2002-08-14 | 2004-02-18 | Mondobiotech Interferon SA | Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation |
| WO2004069174A2 (en) | 2003-01-31 | 2004-08-19 | Slil Biomedical Corporation | Monitoring and treatment of amyotrophic lateral sclerosis |
| BRPI0409250B8 (pt) | 2003-04-08 | 2022-01-18 | Mitsubishi Pharma Corp | Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar |
| US20050042277A1 (en) | 2003-07-17 | 2005-02-24 | Irukulla Srinivas | Pharmaceutical compositions having a swellable coating |
| US20050025825A1 (en) | 2003-07-31 | 2005-02-03 | Xanodyne Pharmacal, Inc. | Tranexamic acid formulations with reduced adverse effects |
| WO2005041988A1 (en) | 2003-10-22 | 2005-05-12 | University Of Florida | Method and composition for pain amelioration |
| CA2555862A1 (en) | 2004-02-13 | 2005-11-10 | Mediquest Therapeutics, Inc. | Polyamine analogs that activate antizyme frameshifting |
| US7445794B1 (en) | 2004-04-29 | 2008-11-04 | The Regents Of The University Of Colorado | Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors |
| JP2008528616A (ja) * | 2005-01-28 | 2008-07-31 | ザンサス ファーマシューティカルズ， インコーポレイテッド | 炎症性疾患および脱髄性疾患を処置するための化合物 |
| CA2617150C (en) | 2005-07-29 | 2016-06-14 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Use of chk2 kinase inhibitors for cancer treatment |
| PL1916995T5 (pl) | 2005-07-29 | 2022-10-31 | Stichting Groningen Centre For Drug Research | Kontrolowany wartością ph impulsowy układ podawczy, sposoby przygotowania i zastosowanie |
| CN101300004B (zh) | 2005-09-23 | 2013-08-21 | 帕瑟洛吉卡有限公司 | 使用多胺类似物治疗病毒感染的方法 |
| WO2007040535A1 (en) | 2005-10-03 | 2007-04-12 | Cellgate, Inc. | Use of polyamine analogs for treatment and prevention of intestinal polyps |
| US20110091418A1 (en) | 2006-09-25 | 2011-04-21 | Pathlogica, LLC | Methods for treating viral infections using polyamine analogs |
| JP4929505B2 (ja) | 2006-10-31 | 2012-05-09 | Ｉｄｅｃ株式会社 | リレーソケット |
| HUE033487T2 (en) | 2007-03-09 | 2017-12-28 | Pathologica Llc | MGBG for osteopontin control and multiple sclerosis treatment |
| CN101918206A (zh) | 2007-03-09 | 2010-12-15 | 赛科股份有限公司 | 再生棉板材及其制备方法 |
| WO2008112251A1 (en) | 2007-03-14 | 2008-09-18 | Progen Pharmaceuticals, Inc. | Cyclopropyl-containing polyamine analogs as disease therapies |
| WO2009018368A1 (en) | 2007-07-30 | 2009-02-05 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| WO2010045265A1 (en) | 2008-10-13 | 2010-04-22 | Biovista, Inc. | Compositions and methods for treating multiple sclerosis |
| WO2010066203A1 (en) | 2008-12-10 | 2010-06-17 | Anhui Zhongren Technology Co., Ltd. | Controlled releasing composition |
| US8080584B2 (en) | 2009-01-23 | 2011-12-20 | Teva Pharmaceuticals Industries, Ltd. | Delayed release rasagiline citrate formulation |
| DK2453886T3 (en) * | 2009-07-16 | 2019-03-25 | Pathologica Llc | ORGANIC ADMINISTRATION COMPREHENSIVE MGBG AND DISEASE METHODS |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| EP2283830A1 (en) | 2009-07-23 | 2011-02-16 | Actogenix N.V. | Aqueous enteric capsule coating |
| EP2343075A1 (en) | 2010-01-04 | 2011-07-13 | Neurotec Pharma, S.L. | Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease |
| TWI590821B (zh) | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | 固體分子分散液 |
| US8858991B2 (en) | 2011-01-19 | 2014-10-14 | Pathologica Llc | Delayed release oral pharmaceutical dosage forms comprising MGBG |
| WO2012112933A1 (en) * | 2011-02-18 | 2012-08-23 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
| AU2014205529B2 (en) | 2013-01-08 | 2018-08-09 | Pathologica Llc | Methods and compositions for treatment of demyelinating diseases |
-
2014
- 2014-01-08 AU AU2014205529A patent/AU2014205529B2/en not_active Ceased
- 2014-01-08 BR BR112015016189A patent/BR112015016189A8/pt not_active Application Discontinuation
- 2014-01-08 WO PCT/US2014/010714 patent/WO2014110154A1/en not_active Ceased
- 2014-01-08 CN CN201480007129.3A patent/CN105163730B/zh not_active Expired - Fee Related
- 2014-01-08 EP EP21152182.8A patent/EP3831372A1/en not_active Withdrawn
- 2014-01-08 US US14/759,599 patent/US10085955B2/en active Active
- 2014-01-08 DK DK14737914.3T patent/DK2943189T3/da active
- 2014-01-08 JP JP2015551862A patent/JP6370804B2/ja not_active Expired - Fee Related
- 2014-01-08 EP EP14737914.3A patent/EP2943189B1/en not_active Not-in-force
- 2014-01-08 ES ES14737914T patent/ES2859553T3/es active Active
- 2014-01-08 CN CN201811424556.8A patent/CN109432073A/zh active Pending
- 2014-01-08 CA CA2896977A patent/CA2896977C/en active Active
-
2015
- 2015-07-08 IL IL239851A patent/IL239851B/en active IP Right Grant
-
2018
- 2018-07-10 JP JP2018130715A patent/JP2018172427A/ja active Pending
- 2018-08-23 US US16/109,824 patent/US10350178B2/en not_active Expired - Fee Related
- 2018-10-15 AU AU2018247351A patent/AU2018247351B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504389A5 (enExample) | ||
| AU2014205529B2 (en) | Methods and compositions for treatment of demyelinating diseases | |
| JP2016535777A5 (enExample) | ||
| JP2015534562A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2007532663A5 (enExample) | ||
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| JP2018111728A5 (enExample) | ||
| JP2006506378A5 (enExample) | ||
| JP2014528474A5 (enExample) | ||
| JP2019512528A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| JP2009504748A5 (enExample) | ||
| JP2019530713A5 (enExample) | ||
| EP4445951A3 (en) | Methods and compositions for treating sleep apnea | |
| WO2014058979A8 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| JP2012517449A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2017501154A5 (enExample) | ||
| JP2016510343A5 (enExample) | ||
| JP2014520856A5 (enExample) | ||
| JP2018512451A5 (enExample) | ||
| JP2013536206A5 (enExample) | ||
| JP2016515137A5 (enExample) | ||
| JP2015529196A5 (enExample) |